Enzo Therapeutics seeks collaborations and partnerships with pharmaceutical and biotechnology companies that will enhance and accelerate drug development and leverage the value of our platform technologies and extensive IP estate.

• We have assigned a high priority to establishing partnerships for our cell signaling modulation programs.
• Other programs that show strong promise for therapeutic applications are available for out-licensing. These include our StealthVector® for HIV; AlequelT, for Crohn's disease; and HBV therapy EHT-899, for hepatitis B.

For additional information, please contact: busdev@enzo.com